New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: A case report

Keyaki Sasaki¹, Tomoaki Morioka¹*, Natsumi Okada², Yuka Natsuki¹, Yoshinori Kakutani¹, Akinobu Ochi¹, Yuko Yamazaki¹, Tetsuo Shoji³, Takashi Ohmura², Masanori Emoto¹

¹Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Department of Internal Medicine, Asakayama General Hospital, Sakai, Japan, and ³Department of Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

Keywords
Fulminant type 1 diabetes, Severe acute respiratory syndrome coronavirus 2, Vaccination

*Correspondence
Tomoaki Morioka
Tel: +81-6-6645-3806
Fax: +81-6-6645-3808
E-mail address: m-tomo@med.osaka-cu.ac.jp

J Diabetes Investig 2022
doi: 10.1111/jdi.13771

ABSTRACT
Fulminant type 1 diabetes is characterized by a rapid progression of insulin deficiency triggered by viral infection. Here, we report a case of a 45-year-old Japanese woman with fulminant type 1 diabetes that developed 8 days after receiving messenger ribonucleic acid vaccine against severe acute respiratory syndrome coronavirus 2. She had been healthy and had no symptoms suggestive of viral infection before the vaccination. Laboratory tests showed exhaustion of insulin secretion and negative results for islet autoantibodies. Human leukocyte antigen genotype analysis showed the DRB1*04:05 and DQB1*04:01 alleles. This is the first case report of new-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination, and suggests that a severe acute respiratory syndrome coronavirus 2 vaccine might trigger the onset of fulminant type 1 diabetes in susceptible individuals. However, a causal relationship remains to be identified, and further studies are required to determine the incidence of such cases.

INTRODUCTION
Fulminant type 1 diabetes is a subtype of type 1 diabetes characterized by rapid onset with ketoacidosis, hyperglycemia with almost normal hemoglobin A1c level and the absence of islet-associated autoantibodies¹. Abnormal immune response triggered by viral infection is suggested as the pathogenesis of the disease, although the precise mechanism remains unclear². Under the current pandemic of coronavirus disease 2019 (COVID-19), over 4 billion people worldwide have received at least one dose of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)². Recently, cases of several kinds of immune-mediated disorders³–⁵, including type 1 diabetes⁶, have been documented after SARS-CoV-2 vaccination. Although a causal relationship remains undefined, these cases suggest an involvement of SARS-CoV-2 vaccination in the onset of autoimmune type 1 diabetes. Here, we report a case of new-onset fulminant type 1 diabetes after the first dose of SARS-CoV-2 vaccine.

CASE REPORT
A 45-year-old Japanese woman, who had stable bronchial asthma, but had never been diagnosed with diabetes, received the first dose of the BNT162b2 messenger ribonucleic acid (mRNA) vaccine (Pfizer-BioNTech). She had a slight fever the next day, and general fatigue and thirst on the third day. Six days after the vaccination, she had nausea and abdominal pain, and visited a family doctor the following day. She was referred to the general hospital 8 days after the vaccination because of hyperglycemia (casual glucose 469 mg/dL, hemoglobin A1c 7.2%). At presentation, she was conscious and hemodynamically stable. She had lost 6 kg since the vaccination, and had a body mass index of 20.6 kg/m². Laboratory examinations showed hyperglycemia, metabolic acidosis with an increased anion gap (25.6 mEq/L) and ketonemia, consistent with diabetic ketoacidosis (Table 1). She promptly received intravenous saline infusion, and intensive insulin therapy with basal insulin glargine and bolus regular insulin with adjustment based on blood glucose levels.

Further examinations showed slightly elevated hemoglobin A1c level, exhaustion of endogenous insulin secretion, negative
results for islet-associated autoantibodies and increased serum levels of pancreatic enzymes (Table 1). Based on these findings, we diagnosed fulminant type 1 diabetes. Immunological tests showed no evidence of recent viral infection potentially triggering type 1 diabetes (parainfluenza virus, coxsackievirus, cytomegalovirus, human herpesvirus and Epstein–Barr virus) and suggested vaccine-induced immunity against SARS-CoV-2 (Table 1). The class II human leukocyte antigen genotypes were DRB1*04:05:01/13:02:01 and DQB1*04:01:01/06:04:01. She eventually achieved adequate glycemic control with insulin glargine U-300 (14 units) before supper and of insulin lispro before meals (8 units, 10 units and 8 units before breakfast, lunch and supper, respectively), and was discharged 12 days after admission.

**DISCUSSION**

To our knowledge, this is the first case of new-onset fulminant type 1 diabetes after SARS-CoV-2 vaccination. Under the current mass SARS-CoV-2 vaccination, there have been a limited number of cases of new-onset type 1 diabetes after vaccination (Table 2). Patrizio et al. reported a case of a 52-year-old man from Italy who developed Graves’ disease and type 1 diabetes 4 weeks after the second dose of BNT162b2 vaccine. We also recently experienced a case of a 51-year-old Japanese woman with acute-onset type 1 diabetes and latent autoimmune thyroiditis 6 weeks after the first dose of Moderna mRNA-1273 vaccine. Although the causal relationship remains undetermined, those two cases suggest that the exposure to
SARS-CoV-2 mRNA vaccine induces type 1 diabetes in healthy individuals, albeit rarely.

Unlike the aforementioned two cases, the present case experienced hyperglycemic symptoms from just 3 days after the first dose of vaccination. Furthermore, our case showed a rapid progression to ketoacidosis, relatively low hemoglobin A1c level and extremely low serum C-peptide level on admission (Table 2). These features suggest a severe immune response causing rapid β-cell destruction and insulin deficiency, consistent with fulminant type 1 diabetes. Because no evidence of viral infection was identified before the onset of hyperglycemia, it cannot be excluded that the SARS-CoV-2 vaccine might have triggered fulminant type 1 diabetes. Of importance, the present case had the human leukocyte antigen DRB1*04:05 and DQB1*04:01 alleles, which confer susceptibility to fulminant type 1 diabetes in Japanese individuals. Thus, it is speculated that a SARS-CoV-2 mRNA vaccination triggers the onset of fulminant type 1 diabetes in genetically susceptible individuals.

The present case is also interesting in terms of the relationship between vaccinations and the development of type 1 diabetes. There is one case report of fulminant type 1 diabetes that developed in a 54-year-old Japanese man 7 days after influenza vaccination. As in the present case, that case had the human leukocyte antigen DRB1*04:05 and DQB1*04:01 alleles. Currently, it is unknown whether mRNA vaccines are more likely to induce autoimmune disorders than other vaccines. As the mRNA vaccine has a unique self-adjuvant property triggering innate immune responses, future studies are required to compare the incidence of autoimmune disorders, including type 1 diabetes, after different types of vaccination.

In summary, we report a case of fulminant type 1 diabetes diagnosed 8 days after the first dose of BNT162b2 SARS-CoV-2 vaccine. This case suggests that SARS-CoV-2 vaccination might be a trigger for the development of fulminant type 1 diabetes in genetically susceptible individuals. However, it remains unclear whether SARS-CoV-2 vaccination is causally associated with fulminant type 1 diabetes or it just coincided with the mass COVID-19 vaccination. Further studies are required to determine the incidence of fulminant type 1 diabetes associated with SARS-CoV-2 vaccination and the causality. To ensure the safety of COVID-19 vaccination, screening for hyperglycemia might be considered after vaccination for susceptible individuals.

ACKNOWLEDGMENTS

This report received no external funding.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Imagawa A, Hanafusa T. Fulminant type 1 diabetes mellitus. Endocr J 2006; 53: 577–584.
2. OurWorldinData. Coronavirus (COVID-19) vaccinations. Statistics and research, 2021. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL Accessed December 5, 2021.

3. Lee E-J, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96: 534–537.

4. Patrizio A, Ferrari SM, Antonelli A, et al. A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun 2021; 125: 102738.

5. Zettinig G, Krebs M. Two further cases of Graves' disease following SARS-Cov-2 vaccination. J Endocrinol Invest 2022; 45: 227–228.

6. Yano M, Morioka T, Natsuki Y, et al. A case of new-onset type 1 diabetes after Covid-19 mRNA vaccination. Intern Med 2022. doi: 10.2169/internalmedicine.9004-21.

7. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 52: 2513–2521.

8. Morgan E, Halliday SR, Campbell GR, et al. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2016; 59: 237–243.

9. Yasuda H, Nagata M, Moriyama H, et al. Development of fulminant type 1 diabetes with thrombocytopenia after influenza vaccination: a case report. Diabet Med 2012; 29: 88–89.

10. Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases". Clin Immunol 2021; 224: 108665.